Adovate Accepted into JLABS, Global Incubator Network
Charlottesville, VA – May 15, 2025 – Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics targeting the adenosine receptors, today announced its acceptance into Johnson & Johnson’s global incubator network, JLABS.
JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers. More information: http://jlabs.jnjinnovation.com/
“We are honored to be part of JLABS, a globally recognized incubator program that fosters scientific discovery and accelerates the development of transformative healthcare solutions,” said William Stilley, Chief Executive Officer of Adovate. “As we continue our efforts to advance our lead compound, ADO-5030, through clinical development, we plan to leverage this membership to navigate key challenges and bring our novel therapy to patients in need.”
About Adovate, LLC
Adovate is a biopharmaceutical company dedicated to inventing and developing best-in-class drug candidates targeting adenosine receptors. Founded in Charlottesville, Virginia, Adovate is at the forefront of novel drug discovery, focusing on adenosine receptor-modulating therapies for respiratory conditions, infectious diseases, cancer, non-opioid pain reduction, and immunological disorders, among others. The Company is actively collaborating with research institutions such as the University of Virginia, Virginia Tech, and the Medical College of Wisconsin to advance its therapeutics pipeline.
Learn more at www.adovate.com.
Forward Looking Statements
This communication contains certain “forward-looking statements” within the meaning of applicable securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding JLABS fostering scientific discovery and accelerating the development of transformative healthcare solutions, JLABS’ support being invaluable in helping Adovate navigate key challenges and bring its novel therapies to patients in need, and Adovate being at the forefront of novel drug discovery. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, Adovate’s ability to develop novel therapeutics targeting the adenosine receptors, JLABS being able to enable and empower innovators and entrepreneurs in pharmaceutical, medical device, consumer and health tech to create and accelerate the delivery of life-enhancing health and wellness solutions, and Adovate inventing and developing best-in-class drug candidates targeting adenosine receptors. These risks should not be construed as exhaustive. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations:
ir@adovate.com
Media Relations:
media@adovate.com